Likewise, regarding, Batoclimab, another FcRn inhibitor used for CIDP treatment, we are also waiting for reports of its long-lasting efficacy and safety.84, 86The use of these therapies is often guided by the need to balance potential benefits with the risk of adverse effects, which can be significant with immunosuppressive drugs. Here, FCGRT is linked to chronic inflammatory demyelinating polyradiculoneuropathy.